Valion Bio, Inc.
For the period ended Jun 30, 2025. Filed Jun 2, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 30, 2025 · Filed Jun 2, 2025
Use the contents to explore the available documents and sections.
Contents
Background
In accordance with the terms of our amended and restated certificate of incorporation, as amended (our “Charter”), our Board is divided into three staggered classes of directors, and each of our directors is assigned to one of the three classes, Class I, Class II and Class III. Currently, our directors are divided among the three classes as follows:
| · | the Class I director is Christina Valauri, and her current term will expire at the Annual Meeting; |
| · | the Class II director is Dean Zikria, and his current term will expire at our 2026 annual meeting of stockholders; and |
| · | the Class III directors are Sheryle Bolton and Jennifer Ernst, and their current terms will expire at our 2027 annual meeting of stockholders. |
The Nominations and Corporate Governance Committee of our Board has recommended, and our Board has nominated, Christina Valauri for re-election as our Class I director at the Annual Meeting for a period of three years, or until her successor is elected and qualified, subject to her earlier death, resignation or removal. At the Annual Meeting, one Class I director will be elected to our Board.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.